Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients

Fig. 1

DNAH mutations that were detected in the 132 TCGA gastric cancer patients who underwent chemotherapy. a For each gene (row) indicated, tumors (columns) with mutations are labeled with red (missense mutations), blue (silent mutations), or brown (frameshift indels) bars. The lower labels with green (sensitive) bars and pink (resistant) bars represent the chemotherapy response status for each individual patient. b Clinicopathologic characteristics of each patient. “Gender” positive/negative indicates male/female; “Garde 1/2” positive/negative indicates that the level of tumor differentiation is well-moderate/poor according to the WHO classification system; “Stage I/II” positive/negative indicates that the tumor stage is I–II/III–IV according to the 7th AJCC cancer staging system; “R0” positive/negative denotes that the microscopic residual tumor was nonexistent/present after gastrectomy. The P value represents the result of the comparison between the patients with DNAH mutations vs those with wild-type DNAH genes; P < 0.05 indicates statistical significance. c Mutation counts for each gene are shown in a

Back to article page